Phase II Trial Results Show Promise for Phenelzine in Prostate Cancer | Cancer Network

Phase II Trial Results Show Promise for Phenelzine in Prostate Cancer | Cancer Network: Phase II trial results found that phenelzine, a monoamine oxidase inhibitor typically used as an antidepressant, showed promise for patients with biochemical recurrent castrate-sensitive prostate cancer.

Comments

Post a Comment

Popular posts from this blog

ASCO 2025: Non-Androgen-Receptor–Driven Prostate Cancer: Updates in Biology, Classification, and Management

Image
New Hope for Aggressive Prostate Cancer: Advances in Understanding and Treating Neuroendocrine Prostate Cancer Revolutionary diagnostic tools and promising new therapies offer renewed hope for patients with treatment-resistant disease What Patients Need to Know For most men with prostate cancer, treatments targeting the androgen receptor (AR) pathway—including hormone therapy and newer drugs like enzalutamide and abiraterone—are highly effective. However, as these treatments have become more successful, doctors have observed an important but concerning phenomenon: some cancers develop resistance by essentially changing their identity. This transformation, called neuroendocrine prostate cancer (NEPC), represents one of the most aggressive forms of the disease. At the recent 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Himisha Beltran from Dana-Farber Cancer Institute presented groundbreaking research that offers new hope for patients facing this challenging ...
Read more

Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey | Prostate Cancer and Prostatic Diseases

Image
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey | Prostate Cancer and Prostatic Diseases Review Article Open access Published: 17 October 2024 Hannah D. McManus ,  Tanya Dorff , Alicia K. Morgans , Oliver Sartor , Neal Shore &  Andrew J. Armstrong   Prostate Cancer and Prostatic Diseases ( 2024 ) McManus, H.D., Dorff, T., Morgans, A.K. et al. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis (2024). https://doi.org/10.1038/s41391-024-00906-z   47 Accesses ...
Read more

The Other Patient: Care for the Caregivers

Image
Informed Prostate Cancer Support Group (IPCSG) Newsletter  |  April 2026 What Our Partners and Caregivers Carry on This Roller Coaster A close look at the hidden burden borne by spouses and care partners across surgery, ADT, radiation, imaging, and theranostics   Prepared for the IPCSG Community  |  April 2026 Bottom Line Up Front (BLUF) When a man is diagnosed with prostate cancer and embarks on treatment — whether surgery, radiation, androgen deprivation therapy (ADT), PSMA imaging, or the newest theranostics — his spouse or care partner shoulders a second, often invisible, patient journey alongside him. Research consistently shows that partners experience rates of anxiety and depression equal to or greater than patients, sacrifice thousands of hours of work and personal time, suffer significant sexual and intimacy losses, and receive far less clinical attention th...
Read more